Table 1 Patient characteristics... | American Society of Hematology

Table 1

Patient characteristics

Characteristic	PBSC		PB		P	Findings of Moss in BM vs PB
Characteristic	Median (range)	SE	Median (range)	SE	P	Findings of Moss in BM vs PB
Age, y	66 (22-70)	3.713	53 (24-72)	2.79	NS
Sex, M/F	11/5	NA	13/13	NA	NS
Diagnosis	7 myeloma, 8 lymphoma, 1 Ewing sarcoma	NA	Healthy	NA	NA	80% primary lung cancer, 20% secondary lung cancer
% CD3⁺CD8⁺	40.9	3.329	27	1.8	**
CD4-CD8 ratio	1.288	0.213	2.358	0.2358	**	Increased CD8⁺ (NS)
% CD8⁺CD45RA^hiCCR7⁺ (naive)	20.56	2.774	50.3	2.354	***	Lower in BM
% CD8⁺CD45RA^loCCR7⁺ (CM)	20.96	3.54	10.2	1.11	*	Equivalent
CD8⁺CD45RA^loCCR7⁻ (EM)	16	3.196	17.3	1.571	NS	Higher in BM
% CD8⁺CD45RA^hiCCR7⁻ (EMR)	19.2	2.589	20	1.16	NS	Lower in BM
% CD8⁺CD62L	14.81	1.615	36.75	24.452	***	Higher in BM
% CD8⁺27⁺28⁺	33.7	5.581	57.75	3.181	*	Higher in BM
% CD8⁺27⁻28⁺	17.1	2.313	7.55	1.157	***	Equivalent
% CD8⁺27⁺28⁻	10.19	1.187	18.8	1.862	***	Equivalent
% CD8⁺27⁻28⁻	30.45	4.818	23.45	3.226	NS	Lower in BM
% CD8⁺CXCR3⁺	2.16	0.67	0.775	0.165	*	Lower in BM
% CD8⁺CCR5⁺	31	3.746	25.13	1.586	*	Higher in BM
% CD8⁺CXCR6⁺	4.745	0.92	2.55	0.53	NS	Higher in BM
% FOXP3⁺CD4⁺	5.35	0.87	6.772	0.54	NS
% EBV latent peptide–specific IFN-γ CD3⁺CD8⁺	0.01	0.1114	0.2	0.5901	*	Equivalent
% EBV lytic peptide–specific IFN-γ CD3⁺CD8⁺	0.605	0.461	1.64	0.984	NS	Higher in BM
% CMV peptide–specific IFN-γ CD3⁺CD8⁺	0.25	0.123	0.59	0.6653	NS	Lower in BM
EBV-DNA copies/10⁶ cells	0 (0-42)	2.871	2685 (0-3614)	251.9	**	Lower in BM

Characteristic	PBSC		PB		P	Findings of Moss in BM vs PB
Characteristic	Median (range)	SE	Median (range)	SE	P	Findings of Moss in BM vs PB
Age, y	66 (22-70)	3.713	53 (24-72)	2.79	NS
Sex, M/F	11/5	NA	13/13	NA	NS
Diagnosis	7 myeloma, 8 lymphoma, 1 Ewing sarcoma	NA	Healthy	NA	NA	80% primary lung cancer, 20% secondary lung cancer
% CD3⁺CD8⁺	40.9	3.329	27	1.8	**
CD4-CD8 ratio	1.288	0.213	2.358	0.2358	**	Increased CD8⁺ (NS)
% CD8⁺CD45RA^hiCCR7⁺ (naive)	20.56	2.774	50.3	2.354	***	Lower in BM
% CD8⁺CD45RA^loCCR7⁺ (CM)	20.96	3.54	10.2	1.11	*	Equivalent
CD8⁺CD45RA^loCCR7⁻ (EM)	16	3.196	17.3	1.571	NS	Higher in BM
% CD8⁺CD45RA^hiCCR7⁻ (EMR)	19.2	2.589	20	1.16	NS	Lower in BM
% CD8⁺CD62L	14.81	1.615	36.75	24.452	***	Higher in BM
% CD8⁺27⁺28⁺	33.7	5.581	57.75	3.181	*	Higher in BM
% CD8⁺27⁻28⁺	17.1	2.313	7.55	1.157	***	Equivalent
% CD8⁺27⁺28⁻	10.19	1.187	18.8	1.862	***	Equivalent
% CD8⁺27⁻28⁻	30.45	4.818	23.45	3.226	NS	Lower in BM
% CD8⁺CXCR3⁺	2.16	0.67	0.775	0.165	*	Lower in BM
% CD8⁺CCR5⁺	31	3.746	25.13	1.586	*	Higher in BM
% CD8⁺CXCR6⁺	4.745	0.92	2.55	0.53	NS	Higher in BM
% FOXP3⁺CD4⁺	5.35	0.87	6.772	0.54	NS
% EBV latent peptide–specific IFN-γ CD3⁺CD8⁺	0.01	0.1114	0.2	0.5901	*	Equivalent
% EBV lytic peptide–specific IFN-γ CD3⁺CD8⁺	0.605	0.461	1.64	0.984	NS	Higher in BM
% CMV peptide–specific IFN-γ CD3⁺CD8⁺	0.25	0.123	0.59	0.6653	NS	Lower in BM
EBV-DNA copies/10⁶ cells	0 (0-42)	2.871	2685 (0-3614)	251.9	**	Lower in BM

Herpesvirus peptide–specific IFN-γ producing CD8⁺ T cells were detected by intracellular cytokine staining by stimulating PB or PBSCs with appropriate HLA class I–restricted viral peptide as previously described.⁸ Intravenous cyclophosphamide (2 g/m²) and subcutaneous G-CSF (10 mcg/kg) were used for PBSC mobilization. Leukapheresis was performed using a Cobe Spectra Gambro BCT continuous flow cell separator.

PBSC indicates peripheral blood stem cells; PB, peripheral blood; BM, bone marrow; NS, not significant; NA, not applicable; IFN-γ, interferon-γ; CM, central memory; EM, effector memory; and EMR, effector memory revertant.

P = .05-.01;

P = .01-.001;

***

P < .001.

View Large

This Feature Is Available To Subscribers Only